NCT02179866View on ClinicalTrials.gov

A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Healthy Volunteer

Interventions

DRUG

RO5285119

Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) \[14C\]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1

Trial Locations (1)

9471 GP

Zuidlaren

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02179866 - A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers | Biotech Hunter | Biotech Hunter